Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. - Wikidata - thesis-toulmin - TriplyDB

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

http://www.wikidata.org/entity/Q34122718

about

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?Targeted drugs in small-cell lung cancer Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy EGFR tyrosine kinase inhibition induces autophagy in cancer cells.Candidate cancer-targeting agents identified by expression-profiling arrays.EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.Multidrug therapy for polycystic kidney disease: a review and perspective.EGFR inhibitors and autophagy in cancer treatment.Integrating network reconstruction with mechanistic modeling to predict cancer therapies.Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine Tumors.Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer.Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas.EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients.

P2860

Q24628852-B8D0F52B-C76A-4231-B661-5B9FDFA8737A Q26748741-0812F6A2-17F8-4B4A-AB04-D62C0F6D72CB Q26767017-924683B2-A8F8-4ABD-B0FF-1321E26BCF88 Q28534819-7082EA19-D13E-4447-BEFA-52CE2A970F57 Q28552225-44F8F8F1-0F34-4CCC-8AB4-22387DE71DA4 Q29249058-D219A231-896A-4999-AC91-F68AE10983A0 Q33409908-3886FE6D-0557-4B97-928D-CA8F5DA4E930 Q35113327-B9E2C193-E7E1-4D09-B1A8-8368D45CA50E Q35605425-806513BF-8167-4ECE-9F6A-D7A22FD3992F Q35623476-0479AC09-0CC1-4BFE-A124-055D617F34F2 Q36524211-B0A3C76B-66E8-41DB-ADB0-EB9E4C7D15E0 Q36802115-5DB6BC90-D50C-456E-890F-51D370B0AEA5 Q37366277-3F5689DE-3739-4F60-9CAF-075C8F4B708C Q38083427-43BA4046-8EC6-45C0-BCBE-029BB07E28CE Q38257898-6A7149D2-BE92-4486-86D8-A4A975BB68FF Q38729295-6C3A57C8-4343-407B-A9A6-EF400B6B62C0 Q38986202-F533022B-6F54-49B5-A646-EC15A87DA5E7 Q39042894-E7BA4146-9854-4304-ACC8-1F257E4D8D14 Q39388106-D05C942F-D17B-45CA-BD5D-75E3278713B4 Q41866875-AAD6702A-2F7F-40EF-9700-17CA4161A1DD Q47130055-C5E1A0EB-12B7-4F94-A39C-D303D31EE5EA Q47132508-BB20B5AF-8FE0-4D10-8C7A-B9012E7F129F Q54222458-7B3C1261-0EDD-4956-A1BE-51B5201C2493

P2860

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

http://www.wikidata.org/entity/Q34122718

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@ast

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@en

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@nl

type

label

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@ast

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@en

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@nl

prefLabel

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@ast

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@en

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.

@nl

P1433

Q34122718-CD024A81-7DBC-4B8D-B8D3-9FE65A94C5A1

P1476

Q34122718-41EF8F7D-D051-481D-9FE1-52CEC5682C1A

P2093

Q34122718-668711F9-03B4-4EE5-A2C1-6DAE59DA79CF

Q34122718-7538305D-D903-40CA-8D92-A73B9E90203C

Q34122718-8B2EA6E5-8424-448C-BAF9-15F7E0410B3B

Q34122718-A6A68290-48A2-4A52-9DBB-EBADA3665000

Q34122718-B0A482A3-9099-4CD2-93D2-56171F8F9F94

Q34122718-BB033201-471E-4198-8B26-60EFB379878B

Q34122718-C3426D91-FC6E-49ED-80A7-C71F4066E2C3

Q34122718-CEC41F7F-2BE2-4949-87BD-EA9B8E8616FB

P2860

Q34122718-15F118B9-CEFE-4E82-B957-8ABAA98629DC

Q34122718-2EEAC005-641A-49A7-BA2C-840E88F771BC

Q34122718-3048BBC5-A6C2-4338-BE7F-B86FA558AD89

Q34122718-37B6D262-8731-477C-BF4C-26A6B45EE961

Q34122718-45F77778-1D55-46A7-A9DE-EFE551BFC921

Q34122718-508E7417-65C4-4E7A-8696-BE5610C2B145

Q34122718-51863CA5-7188-4012-8A86-74872541F0F3

Q34122718-5EA1E144-3DCB-4EE1-B78E-260D8C5306A7

Q34122718-639BADA5-2F53-4C76-9E7E-BF5F7D18B2E0

Q34122718-67659570-D9CD-421E-B486-53AA0B6AD788

P2888

Q34122718-3B13DFD0-E135-4635-95EB-BE41FD19E7D0

P304

Q34122718-9715DFCA-7920-47C4-9235-E945A69D2A14

P31

Q34122718-DD757B21-433F-4354-93E8-21BF8A3A1BCC

P356

Q34122718-FD499015-85CE-4F0C-BB8E-C1ACC82E8DE8

P407

Q34122718-CD33EC2B-263F-40BD-B470-F7F7A742D05D

P433

Q34122718-C50EE7D3-82A0-44A7-A142-D7DF6DE34533

P478

Q34122718-7702DEBB-A25D-4D43-AFBF-5CA248C4B93F

P50

Q34122718-9CB1C9BC-32EE-441E-B766-79A8FB0F1D97

Q34122718-CA00CAFD-1082-4E37-B529-2661FC7DC82F

P577

Q34122718-52B1212F-7AA0-470C-883D-9D6EDFB3B752

P5875

Q34122718-3834B50A-B6A5-4B9A-98A1-3E8A058B77EE

P6179

Q34122718-BD67013E-2CBC-429C-A4FC-21AD2445F308

P698

Q34122718-60CE321E-553E-48B8-AD95-4C202BC4F92C

P932

Q34122718-245B26B9-9F78-48F4-8A5E-85FDC4680D7B

P356

P1433

British Journal of Cancer

P1476

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

@en

P2093

A Haitel

http://www.w3.org/2001/XMLSchema#string

B Herberger

http://www.w3.org/2001/XMLSchema#string

D Cejka

http://www.w3.org/2001/XMLSchema#string

H Hayden

http://www.w3.org/2001/XMLSchema#string

K Schmid

http://www.w3.org/2001/XMLSchema#string

M Filipits

http://www.w3.org/2001/XMLSchema#string

W Sieghart

http://www.w3.org/2001/XMLSchema#string

Z Bago-Horvath

http://www.w3.org/2001/XMLSchema#string

P2860

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

The TOR pathway: a target for cancer therapy

EGFR antagonists in cancer treatment

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (

Treatment options for small cell lung cancer - do we have more choice?

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

P2888

P304

622-628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605761

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Johannes Werzowa

P577

2010-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45494785

http://www.w3.org/2001/XMLSchema#string

P6179

1051616686

http://www.w3.org/2001/XMLSchema#string

P698

20683448

http://www.w3.org/2001/XMLSchema#string

P932

2938245

http://www.w3.org/2001/XMLSchema#string